Access cutting-edge soft tissue sarcoma treatment through this early phase 1 clinical trial at a research site in Philadelphia. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Philadelphia location
Preparing your pre-screening questions…
Access soft tissue sarcoma specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related soft tissue sarcoma treatment provided free
Check if you qualify for this soft tissue sarcoma clinical trial in Philadelphia, PA
No-Cost Study Care
Local to Philadelphia
Convenient for PA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This pilot study will evaluate the feasibility of applying CEUS as imaging guidance for planning RT and predicting RT response. The investigators will determine if US-CT/MRI fusion is feasible and if tumor vascularity and pressure from CEUS can be used to reflect/predict the RT response. The investigators will perform CEUS three times: before the first neoadjuvant RT fraction, halfway through RT, and between the completion of RT and surgery. The fusion will be performed using previously acquired CT/MRI or on-site cone-beam CT with Bmode US. Once the fusion is successful, CEUS will be performed and panoramic 2D images (mimicking 3D) will be collected for the whole tumor. If the fusion is not feasible or successful, the investigators will perform CEUS side by side with CT/MRI and collect images. The investigators will quantify tumoral vascularity comparing Bmode area/volume (total tumor) and contrast-enhanced area/volume (vascular region) at each time point. Subharmonic amplitudes in the tumor area/volume will be quantified to estimate tumoral pressure (known to be the same level as interstitial fluid pressure (IFP)). Quantified vascularity and pressure at each time point will be compared with the tumor size change at later study points as well as the histological outcome after the surgery.
Sponsor: Thomas Jefferson University
Yes, this clinical trial (NCT07436364) has an active research site in Philadelphia, PA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for soft tissue sarcoma treatment options in Philadelphia, PA, this clinical trial (NCT07436364) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Philadelphia research site is actively enrolling participants for this early phase 1 clinical trial. You'll receive care from experienced soft tissue sarcoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all soft tissue sarcoma clinical trials near you to find additional studies recruiting in your area.
See all sarcoma clinical trials recruiting in Philadelphia — not just this study.
Browse Sarcoma Trials in Philadelphia →